KURA

Kura Oncology, Inc.

KURA | $17.15 -3.0% 460K

(0.0% 1d) (-18.0% 1m) (67.0% 1y) (0.0% 2d) (0.0% 3d) (-5.4% 7d) (-19.58% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 1,306,497,633
http://www.kuraoncology.com
Sec Filling | Patents | 60 employees

(US) Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

cancer leukemia msa treatment

add to watch list Paper trade email alert is off

Press-releases

Kura Oncology to Participate in Stifel Targeted Oncology Forum
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
KURA | $17.15 -3.0% 460K

Health Technology

| -11.2% | O: -0.94% H: 0.85% C: -0.85%

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-05 (Crawled : 12:00) - globenewswire.com
KURA | $17.15 -3.0% 460K

Health Technology

| -14.11% | O: -4.08% H: 3.53% C: 1.34%
nasdaq grants

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 5, 2024
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
KURA | $17.15 -3.0% 460K

Health Technology

| -14.11% | O: -4.08% H: 3.53% C: 1.34%
nasdaq grants

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Published: 2024-03-06 (Crawled : 12:30) - globenewswire.com
KURA | $17.15 -3.0% 460K

Health Technology

| -14.5% | O: 1.28% H: 8.54% C: 6.52%
ko-2806 first renal cell trial plus

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-01 (Crawled : 22:00) - globenewswire.com
KURA | $17.15 -3.0% 460K

Health Technology

| Email alert Add to watchlist
nasdaq grants

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 21:00) - globenewswire.com
KURA | $17.15 -3.0% 460K

Health Technology

| -17.33% | O: -0.05% H: 3.6% C: -1.7%
year financial results

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
Published: 2024-02-26 (Crawled : 12:30) - globenewswire.com
KURA | $17.15 -3.0% 460K

Health Technology

| -11.16% | O: -0.15% H: 4.01% C: 2.57%
komet-008 first leukemia trial

Kura Oncology to Participate in Three Upcoming Investor Conferences
Published: 2024-02-22 (Crawled : 12:30) - globenewswire.com
KURA | $17.15 -3.0% 460K

Health Technology

| -10.01% | O: 1.1% H: 0.35% C: -3.07%

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-20 (Crawled : 12:30) - globenewswire.com
KURA | $17.15 -3.0% 460K

Health Technology